Cancer NetworkOriginal article
<![CDATA[Soquelitinib Monotherapy Yields Durable Responses in Peripheral T-Cell Lymphoma ]]>
Phase 1positivesoquelitinibPositive
AI Analysis
Summary
Final Phase 1/1b data for soquelitinib monotherapy demonstrated a 37.5% objective response rate and 28.1-month median overall survival in peripheral T-cell lymphoma patients with prior treatment experience.
Clinical Trial Data
Phase
1/1b
Primary Endpoint
Met
Outcome Details
37.5% ORR and 28.1-month median OS in patients with 1-3 prior lines of therapy
Importance:6/10
Sentiment:
0.70
oncologyT-cell lymphomaPhase 1/1bmonotherapyclinical data
Related Companies
Read the original article
Published by Cancer Network on August 27, 2026 4:00 PM